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Abstract
Cigarette smoking and poor air quality are the greatest risk factors for developing COPD,

3

but growing evidence indicates genetic factors also affect predisposition to and clinical

4

expression of disease. With the exception of α1-Antitrypsin deficiency (AATD), a rare

5

autosomal recessive disorder that is present in 1-3% of individuals with COPD, no single gene is

6

associated with the development of obstructive lung disease. Instead, a complex interplay of

7

genetic, epigenetic, and environmental factors are the basis for persistent inflammatory

8

responses, accelerated cell aging, cell death, and fibrosis, leading to the clinical symptoms of

9

COPD and different phenotypic presentations. In this brief review, we discuss current

10

understanding of the genetics of COPD, pathogenetics of AATD, epigenetic influences on

11

development of obstructive lung disease, and how classifying COPD by phenotype can influence

12

clinical treatment and patient outcomes.

13
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Introduction
Chronic obstructive pulmonary disease (COPD) affects approximately 6.4% of the U.S.

3

adult population. It is the third leading cause of death worldwide, with estimated U.S. direct

4

costs of 49 billion dollars annually (National Center for Health Statistics, 2016). Cigarette

5

smoking and poor air quality are the greatest risk factors for COPD (GBD Chronic Respiratory

6

Disease Collaborators, 2017), but there is growing evidence that genetic factors affect

7

predisposition to and clinical expression of disease. Having a family history (FH) of COPD

8

markedly increases an individual's risk of developing disease, especially in people who smoke.

9

Compared to smokers without FH of COPD, smokers whose parents had COPD were three times

10

as likely to develop disease, but non-smokers with FH of COPD had no increased risk compared

11

to non-smokers without FH (Zhou et al., 2013). Thus, development of COPD is attributable to a

12

combination of environmental and genetic factors.

13

Genetics

14

With the exception of α1-Antitrypsin deficiency (AATD), which occurs in 1-3% of

15

patients with COPD, no single gene is associated with the development of obstructive lung

16

disease (Sakornsakolpat et al., 2019). AATD is a rare disorder typically seen in people of

17

European ancestry. Among people with AATD, Pulmonary disease occurs primarily as a result

18

of abnormally shaped α1-Antitrypsin proteins (AAT) synthesized by the liver, rather than from

19

environmental exposures. Normally, AAT protects lung tissue from being damaged by cytotoxic

20

enzymes secreted by roaming neutrophils, a subset of white blood cells that act as first-

21

responders in non-specific immunity. However, in AATD, the abnormal proteins do not function

22

correctly and are instead retained in the liver, causing cirrhosis and progressive lung damage

23

through loss of neutrophil elastase inhibition (Strnad, McElvaney, & Lomas, 2020).
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Misfolded AAT proteins are created due to a single DNA point mutation (change in one

25

nucleotide base pair) at the allele SERPINA1, located on chromosome 14. An allele is a gene

26

pair, with one gene derived from each parent. AAT alleles can be homozygous (same genetic

27

sequence on chromosome 14) or heterozygous (different genetic sequences). These variations

28

are called protease inhibitor (PI*) types, and are used to classify AATD. The unusual taxonomy

29

is based on nomenclature created prior to the identification of the SERPINA1 allele (Stoller,

30

Hupertz, & Aboussouan, 2020).

31

PI*M is the predominant (normal) AAT allele, whereas PI*Z is the most common

32

pathologic allele, followed by variants of PI*S, PI*I, and PI*F (Miravitlles et al., 2017).

33

Homozygous individuals without AATD would thus have the genotype PI*MM (i.e. two normal

34

PI*M genes). Because AATD is an autosomal recessive disorder, an individual must have two

35

abnormal genes to express disease. Therefore, an individual without clinical disease could also

36

have genotype PI*MZ or PI*MS (one normal and one disease allele). Similarly, an individual

37

with AATD could have genotype PI*ZZ, PI*ZS, or any other combination of two disease alleles.

38

AATD ranges from mild to severe, depending on the pathogenic variant of the PI* mutations.

39

For heterozygous individuals with one normal gene (PI*M), risk of developing obstructive lung

40

disease may still be elevated, even though clinical AATD is not present.

41

For the preceding reasons, in addition to usual COPD management, AATD should be

42

treated with intravenous infusion of plasma-purified AAT protein to promote correct immune

43

functioning and to slow the progression of emphysema (Miravitlles et al., 2017). Thus, while a

44

rare disorder, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines

45

recommend that all individuals with COPD should be tested for AATD to facilitate identification
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and proper treatment of affected individuals (Global Initiative for Chornic Obstructive Lung

47

Disease, 2021).

48

Like asthma and other complex diseases, COPD is otherwise genetically heterogenous,

49

with wide variability in genes, disease expression, progression, and subjective symptomatology

50

(Corlateanu et al., 2020). Prior to the advent of economical whole-genome sequencing, studies

51

in COPD genetics focused primarily on identifying discrete, shared DNA variations specific to

52

affected, related individuals (i.e. linkage studies). This was done by examining a series of

53

"candidate genes" thought to be related to COPD. However, linkage studies were unsuccessful

54

in finding any monogenic patterns of heredity, as occurs in other respiratory conditions like AAT

55

and cystic fibrosis.

56

With increasingly economical whole-genome sequencing, research into COPD genetics

57

transitioned from linkage studies to genome-wide association studies (GWAS), which enable the

58

examination of subtle variations in DNA across the entire genome, along with associations

59

between genetic patterns, clinical traits, and treatment responsiveness (Visscher et al., 2017).

60

Researchers using this approach have identified 156 different genes at 82 significant loci, of

61

which >15% overlap with asthma and pulmonary fibrosis (Sakornsakolpat et al., 2019).

62

The importance of genetics for COPD lies in the fact that inflammatory responses, which

63

modulate disease progression and clinical presentation, are driven by DNA. Genetic code

64

defines how and when inflammatory mediators are created, and how noxious stimuli (e.g.

65

particulates) are perceived and processed. Cigarette smoking, the primary cause of COPD,

66

exposes lung tissue to elevated levels of reactive oxygen species (ROS). Excess ROS damages

67

DNA and leads to increased expression of genes that control inflammation through altered

68

activity of intracellular mediators, most commonly Nuclear factor E2-related factor (Nrf2). Nrf2
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regulates hundreds of genes downstream, and is central to cellular management of oxidative

70

stress and inflammation. With dysregulation of Nrf2, cellular stress and aging are greatly

71

accelerated. These intracellular changes cause the release of pro-inflammatory mediators into

72

the extracellular space. Chemical messengers then attract other inflammation-regulating cells

73

(e.g. macrophages, neutrophils, T-helper cells), which precipitate the release of additional

74

cytotoxic chemokines and cytokines (commonly interleukins), further damaging surrounding

75

tissues. Cumulatively, these processes form a reinforcing cycle of damage, inflammation,

76

accelerated cell death, and fibrosis (Hikichi, Mizumura, Maruoka, & Gon, 2019). It is also worth

77

noting that like asthma, inflammation in COPD can be mediated by different T-helper (Th)

78

pathways. Inflammation in COPD typically follows Th1 and Th17 pathways (also known as

79

Type 1 non-allergic airway inflammation), but may also be mediated by Th2 pathways. This has

80

been referred to as Type 2 (allergic) airway inflammation or Type 2 COPD (Oishi, Matsunaga,

81

Shirai, Hirai, & Gon, 2020). It has been suggested that the inflammatory mechanism via

82

different T-helper pathways may underlie variable responsiveness to treatments; Th2 pathways

83

are susceptible to use of inhaled corticosteroids (ICS), whereas Th1 and Th17 pathways have

84

poor ICS-responsiveness.

85

Epigenetics

86

Early stage evidence indicates that epigenetic influences also play an important role in

87

COPD development through a secondary process called DNA methylation (He, Tang, Huang, &

88

Li, 2020). Methylation occurs when a histone molecule becomes entangled with a portion of

89

DNA, blocking translation and effectively "silencing" that section of genetic code. (This can be

90

conceptualized as bubble gum tangled in a strand of hair.) Methylation is actually a normal

91

process and acts as an essential on/off switch for gene expression during growth and
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development. However, abnormal methylation causes increased down-regulation of protective

93

genes, contributing to accelerated cellular aging and death (Du et al., 2019). Furthermore,

94

evidence indicates that prenatal smoke exposure might also increase risk for later developing

95

COPD through epigenetic mechanisms, as hyper-methylated DNA has been observed in the cord

96

blood of infants exposed to cigarette smoke in utero (Krauss-Etschmann, Meyer, Dehmel, &

97

Hylkema, 2015). This suggests that exposure to environmental toxins could have prolonged

98

epigenetic effects contributing to development of disease. Because methylation is reversible, it

99

is hypothetically amenable to targeted drug therapy, and is therefore an area of active

100

pharmaceutical research.

101

Clinical Phenotypes

102

Consistent with the complex underlying genetics, clinical presentation of COPD is also

103

highly variable. Once treated as a single entity, COPD is now considered to be an umbrella term

104

with several distinct phenotypes (Sakornsakolpat et al., 2019). Phenotypes are essentially sub-

105

groups within COPD that have shared clinical characteristics of obstructive lung disease, but also

106

have clinically important between-group differences, such as who is typically affected, patterns

107

of symptoms and disease progression, and variable responsiveness to treatments. Classifying

108

and treating COPD by phenotype can help to predict outcomes and improve clinical

109

management.

110

The first phenotypic classification system for COPD was proposed in 1989, and included

111

chronic bronchitis, emphysema, and asthma (Snider, 1989). Since then, multiple taxonomies

112

have been proposed, with currently accepted phenotypes including AATD, chronic bronchitis,

113

emphysema, frequent exacerbator and rare exacerbator (Corlateanu et al., 2020). Asthma and

114

COPD are now considered fully-distinct diseases entities, albeit sharing common characteristics,
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and the use of "Asthma-COPD overlap" is no longer encouraged (Global Initiative for Chornic

116

Obstructive Lung Disease, 2021). Emerging evidence points to additional phenotypic variations

117

that may include a "no smoking COPD" group or overlap with other co-morbidities such as

118

bronchiectasis.

119

Implications for Practice

120

Since 2011, GOLD guidelines for pharmacologic management of COPD have capitalized

121

on four broad phenotypic groupings to determine the most appropriate first line therapy, based

122

on responsiveness to treatment (Global Initiative for Chornic Obstructive Lung Disease, 2021).

123

These phenotypes (GOLD Group A, B, C, D) are clustered by two clinical characteristics: risk of

124

exacerbation with or without hospitalization (low risk/high risk) versus overall symptom burden

125

(low symptoms/high symptoms). While spirometric classification is assessed (grade of FEV1%

126

predicted),

127

efficacy. Serum eosinophil counts (>100-300 cell/μL) can be predictive of ICS responsiveness

128

and Type 2 airway inflammation, and can help to determine if inhaled or oral corticosteroids

129

could be beneficial. At present, biomarkers, genomic, and pharmacogenetic testing are not

130

recommended for clinical management, with the exception of AATD testing, which should be

131

performed once for all patients with COPD (ICD-10-CM code E88.01). If not covered by

132

insurance, free confidential DNA test kits are available to providers or patients directly (Alpha-1

133

Foundation, n.d.). Similarly, most contemporary direct-to-consumer genetic testing services can

134

identify SERPINA1 variants (Hersh, Campbell, Scott, & Raby, 2019; Horton et al., 2019).

it is not used as a sole factor in treatment selection, as there is no evidence to support

135
136

Conclusion
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In conclusion, COPD is a common, preventable inflammatory disease that occurs due to a

138

complex interplay of genetic and environmental factors. Current understanding of COPD

139

supports use of broad phenotypic categories to inform clinical management and predict

140

outcomes. Increased understanding of genetic and epigenetic factors will likely result in

141

increasingly targeted treatment options over time.

142
143
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